Public Citizen stressed that it supports efforts to lower drug costs for people in America, while caveating that the MFN deals as understood—and with added color from companies on the policy’s ...

The government has announced pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s drug spend.

Medicare's new MFN drug pricing plan could save $11.6 billion by anchoring US prices to foreign benchmarks, but side deals and lawsuits may erase most gains.

But Congress should reject any effort to codify “Most Favored Nation” drug pricing—whether as a broad mandate, a limited ...

Trump says all 50 states have joined his Medicaid drug-pricing plan as Democrats seek to keep healthcare central in the ...

With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial ...

On August 31, the Trump Administration expanded its Most-Favored-Nation (MFN) drug pricing initiative by securing agreements ...

Congress should be cautious about turning Most-Favored-Nation drug pricing into permanent law. Codification could lock in an opaque, foreign-reference pricing regime that may deliver headline ...

These deals will require the companies to provide MFN prices to state Medicaid programmes nationally.

What’s new: The U.S. administration’s most-favored-nation (MFN) drug pricing initiative intends to align U.S. drug prices with those in comparable developed nations through executive orders, ...